• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Evotec SE

    11/29/24 10:38:17 AM ET
    $EVO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EVO alert in real time by email
    6-K 1 evo_6k.htm FORM 6-K evo_6k.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of November, 2024

     

    COMMISSION FILE NUMBER 001-34041

     

    Evotec SE

    (Translation of registrant’s name into English)

     

    Essener Bogen 7

    22419 Hamburg

    Germany

    Tel: +49 40 560810

    (Address of principal executive offices)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20‑F or Form 40‑F: Form 20‑F ☒   Form 40‑F ☐

     

    Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(1):   ☐

     

    Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(7):   ☐

     

     

     

     

    On November 29, 2024, Evotec SE (the “Company”) issued a press release announcing a change in Management Board. A copy of the press release is attached as Exhibit 99.1 hereto.

     

    EXHIBIT INDEX

     

    Exhibit

     

    Description of Exhibit

    99.1

     

    Evotec announces change in Management Board

                 

     

    2

     

     

    SIGNATURE

     

    Pursuant to the requirements, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

     

    Evotec SE

           
    By: /s/ Christian Wojczewski

     

     

    Name: Christian Wojczewski

     
       

    Title: Chief Executive Officer

     
    Date: November 29, 2024    

     

     

    3

     

    Get the next $EVO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EVO

    DatePrice TargetRatingAnalyst
    4/24/2025Sell → Hold
    Deutsche Bank
    10/7/2024Buy → Hold
    Jefferies
    8/8/2024Hold → Sell
    Deutsche Bank
    7/29/2024$15.00 → $6.00Overweight → Equal-Weight
    Morgan Stanley
    7/11/2024Buy → Hold
    Deutsche Bank
    4/12/2024Hold → Buy
    Deutsche Bank
    1/18/2024Sector Perform → Outperform
    RBC Capital Mkts
    6/23/2023$12.00 → $16.00Equal-Weight → Overweight
    Morgan Stanley
    More analyst ratings

    $EVO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Evotec SE upgraded by Deutsche Bank

      Deutsche Bank upgraded Evotec SE from Sell to Hold

      4/24/25 7:18:16 AM ET
      $EVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evotec SE downgraded by Jefferies

      Jefferies downgraded Evotec SE from Buy to Hold

      10/7/24 7:52:16 AM ET
      $EVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evotec SE downgraded by Deutsche Bank

      Deutsche Bank downgraded Evotec SE from Hold to Sell

      8/8/24 8:58:18 AM ET
      $EVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EVO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Evotec Receives Grant from Korean Government to Develop Novel Antibody-based Treatments for Lung Diseases

      Yonsei University, Zymedi and Evotec receive US$ 4.5m grant from the Korea Institute of Advanced Technology under the Korean Ministry for Trade, Industry and EnergyFunding supports a novel collaboration to develop first-in-class therapeutic antibodies to treat asthma and idiopathic pulmonary fibrosis HAMBURG, GERMANY / ACCESS Newswire / January 22, 2025 / Evotec SE ((Frankfurt Stock Exchange:EVT, MDAX/TecDAX, TRQX:EVTd, NASDAQ:EVO) announced that, together with Yonsei University and the Korean biotech company Zymedi, it will receive a US$ 4.5m grant from the Korea Institute of Advanced Technology (KIAT). The KIAT grant will fund the development of first-in-class biologic therapies to treat l

      1/22/25 2:00:00 AM ET
      $EVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evotec SE announces first projects for LAB eN(2) drug discovery accelerator with Novo Nordisk

      Novo Nordisk and Evotec select three projects from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center to be developed within LAB eN² focusing on cardiometabolic diseasesLAB eN² is also expanding, adding Boston Children's Hospital, Boston University, Johns Hopkins University, Joslin Diabetes Center, and the Icahn School of Medicine at Mount Sinai as new participating institutions HAMBURG, DE / ACCESSWIRE / December 11, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)((SDAX/TecDAX, TRQX:EVTd)(NASDAQ:EVO) announced that its translational drug discovery accelerator with Novo Nordisk, LAB eN², which aims to nurture early research from acade

      12/11/24 2:00:00 AM ET
      $EVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evotec Announces Change in Management Board

      Dr Craig Johnstone steps down as Chief OperatingOfficer effective 31 December 2024Distribution of responsibilities internally HAMBURG, GERMANY / ACCESSWIRE / November 29, 2024 / Evotec SE ((Frankfurt Stock Exchange: EVT, SDAX/TecDAX, TRQX:EVTd, NASDAQ:EVO) today announced that its Chief Operating Officer, Dr Craig Johnstone, will step down and leave the Company effective 31 December 2024. Dr Johnstone joined Evotec in May 2012 as SVP Drug Discovery and Innovation Efficiency and in April 2015 was named President and Site Head, Evotec (France) SAS. Dr. Johnstone was appointed Global Head, Integrated Drug Discovery in January 2017 and became Chief Operating Officer and a member of the Managemen

      11/29/24 2:00:00 AM ET
      $EVO
      Biotechnology: Pharmaceutical Preparations
      Health Care